title: Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna in Egypt.
abstract: A study of the acceptability of two once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt included 1091 women participating in the clinical trial of the two methods carried out during the period from November 1989 to July 1992. The acceptability of the two contraceptives proved to be high when measured by the rate of continuation at 12 months of injectable use, by method satisfaction, service satisfaction, rec recommending use to others, intent of future use, as well as willingness to pay for them when the injectables are marketed. The most important determinants of use discontinuation were young age, large family size, first time contraceptive use, previous experience with menstrual problems, dissatisfaction with clinic services, lack of counseling, lack of social support, as well as the husband's negative attitude towards contraceptive use. Side effects were more frequently reported by discontinuers; however, continuers appeared to be more tolerant of the same side effects. This study provided in-depth information about the social aspects affecting the acceptability of monthly injectable contraceptives in the different Egyptian localities, in addition to its being useful in monitoring activities in the clinical setting during these trials.
authors.affiliation: Ob/Gyn Dept., Mansoura University, Cairo, Egypt.
authors.forename: E O
authors.initials: EO
authors.lastname: Hassan
authors.forename: N
authors.initials: N
authors.lastname: el-Nahal
authors.forename: M
authors.initials: M
authors.lastname: el-Hussein
mesh_terms: D001290:Attitude; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004534:Egypt; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008393:Marriage; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017060:Patient Satisfaction; D012189:Retrospective Studies; D011795:Surveys and Questionnaires
chemical_list: D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004338:Drug Combinations; C418365:estradiol, norethindrone drug combination; D004958:Estradiol; C034528:CycloProvera; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone